[A20-71] Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V

Last updated 16.11.2020

Project no.:
A20-71

Commission:
Commission awarded on 12.08.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Airways and respiratory system

Indication:

Adults with chronic progressive fibrosing interstitial lung diseases other than SSc-ILD or IPF

Result of dossier assessment:

The advantage in the outcome category of morbidity is accompanied by disadvantages in side effects; indication of minor added benefit

Federal Joint Committee (G-BA)

2021-02-04: A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form